Evidence map›Paper›PMID 30270043›Full record

ArticleCell2018

RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses.

Todd Bradley, Dimitra Peppa, Isabela Pedroza-Pacheco, Dapeng Li, Derek W Cain, Ricardo Henao, Vaishnavi Venkat, Bhavna Hora, Yue Chen, Nathan A Vandergrift and 11 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06626555 (Pilot, Randomized, Open-Label, Non-Active Comparator Controlled Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 Infection), which is not on this map. Cited by 70 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06626555 phase2not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Pilot, Randomized, Open-Label, Non-Active Comparator Controlled Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 Infection

TypeinterventionalSponsorUniversity College, LondonRan2024 to 2026Enrolled36ConditionsHIVArmsLetermovir
3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Protein/AS01Cell reports. Medicine · 2021
    Trial
  3. Priming of Multiple HIV Neutralizing B Cell Precursors in Humans.medRxiv : the preprint server for health sciences · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Unconventional functions of natural killer cells in homeostasis and disease.Journal of immunology (Baltimore, Md. : 1950) · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Exosomes derived from umbilical cord blood NK cells inhibit the progression of pancreatic cancer by targeting ROS-mediated mitochondrial dysfunction.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025
    Article
  17. Article
  18. Article
  19. Review
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 2 countries.

Todd BradleyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA. Electronic address: todd.bradley@duke.edu.
Dimitra PeppaNuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7FZ, UK.
Isabela Pedroza-PachecoNuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7FZ, UK.
Dapeng LiDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Derek W CainDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
Ricardo HenaoCenter for Applied Genomics and Precision Medicine, Duke University, Durham, NC 27710, USA.
Vaishnavi VenkatCenter for Applied Genomics and Precision Medicine, Duke University, Durham, NC 27710, USA.
Bhavna HoraDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Yue ChenDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Nathan A VandergriftDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
R Glenn OvermanDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
R Whitney EdwardsDepartment of Surgery, Duke University, Durham, NC 27710, USA.
Chris W WoodsDepartment of Medicine, Duke University School of Medicine, Durham, NC 27710, USA; Center for Applied Genomics and Precision Medicine, Duke University, Durham, NC 27710, USA.
Georgia D TomarasDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke University, Durham, NC 27710, USA; Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA.
Guido FerrariDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke University, Durham, NC 27710, USA.
Geoffrey S GinsburgDepartment of Medicine, Duke University School of Medicine, Durham, NC 27710, USA; Center for Applied Genomics and Precision Medicine, Duke University, Durham, NC 27710, USA.
Mark ConnorsLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
Myron S CohenUniversity of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
M Anthony MoodyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710, USA; Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA.
Persephone BorrowNuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7FZ, UK. Electronic address: persephone.borrow@ndm.ox.ac.uk.
Barton F HaynesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA; Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA. Electronic address: barton.haynes@duke.edu.
Duke University · USUniversity of Oxford · GBNational Institute of Allergy and Infectious Diseases · USUniversity of North Carolina at Chapel Hill · US

Funding

Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2012 to 2018
$204.7M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
Mechanisms of Effective Humoral Immune Responses to HIV-1ZIAAI001090 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CONNORS, MARK · 2009 to 2025
$14.8M
Data commons for 'omic, microscopy and analysis core facilitiesS10OD018164 · OD · DUKE UNIVERSITY · PI WRAY, GREGORY A. · 2014 to 2014
$598k
Medical Research Council MR/K012037/1Medical Research Council MR/M008614Medical Research Council MR/M008614/1Medical Research Council MR/M008614/2NIAID NIH HHS P30 AI064518NIAID NIH HHS UM1 AI100645NIH HHS S10 OD018164
6 · The paper itself

Abstract

HIV-1 broadly neutralizing antibodies (bnAbs) are difficult to induce with vaccines but are generated in ∼50% of HIV-1-infected individuals. Understanding the molecular mechanisms of host control of bnAb induction is critical to vaccine design. Here, we performed a transcriptome analysis of blood mononuclear cells from 47 HIV-1-infected individuals who made bnAbs and 46 HIV-1-infected individuals who did not and identified in bnAb individuals upregulation of RAB11FIP5, encoding a Rab effector protein associated with recycling endosomes. Natural killer (NK) cells had the highest differential expression of RAB11FIP5, which was associated with greater dysregulation of NK cell subsets in bnAb subjects. NK cells from bnAb individuals had a more adaptive/dysfunctional phenotype and exhibited impaired degranulation and cytokine production that correlated with RAB11FIP5 transcript levels. Moreover, RAB11FIP5 overexpression modulated the function of NK cells. These data suggest that NK cells and Rab11 recycling endosomal transport are involved in regulation of HIV-1 bnAb development.

Indexed as

Adaptor Proteins, Signal TransducingAdultAIDS VaccinesAntibodies, NeutralizingB-LymphocytesCell LineCohort StudiesFemaleGene Expression ProfilingHIV-1HIV AntibodiesHIV InfectionsHumansKiller Cells, NaturalMaleMiddle AgedAdaptor Proteins, Signal TransducingAIDS VaccinesAntibodies, NeutralizingHIV AntibodiesRAB11FIP5 protein, humanbroadly neutralizing antibodiesHIV-1natural killer cellsRab11fip5recycling endosomesvaccine

Identifiers

PMID30270043
PMCPMC6176872
OpenAlexW2892494775

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.